Atorvastatin for the treatment of plaque-type psoriasis

Pharmacotherapy

Volumn 31, Issue 11, 2011, Pages 1045-1050

  Faghihi, Toktam ^a   Radfar, Mania ^a   Mehrabian, Zohre ^a   Ehsani, Amir Hoshang ^b   Hemami, Mohsen Rezaei ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Atorvastatin; Pleiotropy; Psoriasis; Statin

Indexed keywords

ATORVASTATIN; CORTICOSTEROID; EMOLLIENT AGENT; FLUOCINOLONE ACETONIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KERATOLYTIC AGENT; PLACEBO; SALICYLIC ACID; TRIAMCINOLONE ACETONIDE;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BODY SURFACE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PLAQUE TYPE PSORIASIS; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; PYRROLES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054950827     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.11.1045     Document Type: Article

References (32)

1. Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies - U.S. experience. Br J Dermatol 2004;151:3-15. (Pubitemid 39061275)
2. Monteleone G, Pallone F, MacDonald TT, Chimenti S, Costanzo A. Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci 2010;120:1-11.
3. Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J 2010;16:2.
4. Miteva M. Psoriasis: targeting therapy towards the inflammatory cascade. Am J Clin Dermatol 2010;11(suppl 1);11-13.
5. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Antiinflammatory and immunomodulatory effects of statins. Kidney Int 2003;63:12-23.
6. Yildirir A, Muderrisoglu H. Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2004;2:309-18. (Pubitemid 39200180)
7. Danesh FR, Anel RL, Zeng L, Lomasney J, Sahai A, Kanwar YS. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp 2003;51:139-48. (Pubitemid 36828176)
8. Biasucci LM, Biasillo G, Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010;48:1685-91.
9. Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp 2009;57:243-51.
10. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010;7:284-9.
11. Vizzardi E, Raddino R, Teli M, Gorga E, Brambilla G, Dei Cas L. Psoriasis and cardiovascular diseases. Acta Cardiol 2010;65:337-40.
12. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130:1785-96.
13. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications - report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-55. (Pubitemid 47389868)
14. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010;2:23-30.
15. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73. (Pubitemid 46934281)
16. Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008;159(suppl 2):10-17.
17. Egesi A, Sun G, Khachemoune A, Rashid RM. Statins in skin: research and rediscovery, from psoriasis to sclerosis. J Drugs Dermatol 2010;9:921-7.
18. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-9. (Pubitemid 38868205)
19. Ghazizadeh R, Tosa M, Ghazizadeh M. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 2011;341:394-8.
20. Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol 2010;49:1235-43.
21. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(suppl 2):ii65-8. (Pubitemid 40288526)
22. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28.
23. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study [letter]. J Am Acad Dermatol 2007;57:529-31. (Pubitemid 47239149)
24. Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 2010;19:58-61.
25. Colsman A, Sticherling M. Simvastatin in psoriasis: ambiguous effects [letter]. Acta Derm Venereol 2010;90:411.
26. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? what constitutes a clinically significant improvement when treating psoriasis. J Am Acad Dermatol 2000;43:281-5. (Pubitemid 30626007)
27. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol 2010;21:298-304.
28. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16. (Pubitemid 39223221)
29. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
30. Reich K, Signorovitch J, Ramakrishnan K, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 2010;63:1011-18.
31. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
32. Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970-5. (Pubitemid 44145036)